AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$DNA

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform:

Original reporting
SEC EDGAR 8-K
Published Nov 5, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DNA
Bearish
medium confidence
Mentioned
$DNA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DNABearishLow
01

Why it matters

The Q3 earnings release provides fresh financial data and raised cash burn guidance, which may influence short-term trading.

02

Market read

The filing offers new earnings data for a niche biotech services firm, with modest immediate market impact but potential longer-term relevance due to government contracts.

03

What to watch

Strong cash position of $285M and new government contracts could support future upside.

Relevance 7/10Novelty 7/10Timing: same day release

Background

Ginkgo Bioworks provides autonomous lab platforms and cloud lab services to pharma, AI labs, and government agencies.

Company-level read

Ticker impact

$DNABearishMedium confidence
Context

Ginkgo Bioworks disclosed Q3 2026 results, reporting $28M revenue (down 6%) and a GAAP net loss of $41M.

Expected impact

likely pressure as investors price in weaker revenue and continued losses

Evidence & confidence

Quarterly results are a primary disclosure; the modest revenue decline and sizable loss suggest short-term downside.

Market effects

Sector

Highlights ongoing demand for autonomous lab services in biotech and pharma.

Regional

U.S. biotech sector may see modest impact from the earnings miss.

Global

Limited; the company is niche with modest global footprint.

Counterpoint

What could challenge this read

If the market overreacts to the loss, the stock could rebound on the long-term growth narrative.

Key entities

  • company
    Ginkgo Bioworks Holdings, Inc.

    Provider of autonomous laboratory platforms and cloud lab services.

  • company
    Novo

    Top-tier pharma customer that purchased an autonomous lab.

Read at source← All news

Related articles

$DNAMed

Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Ginkgo Bioworks (NYSE:DNA) reported a strategic shift toward commercializing autonomous lab hardware and cloud services during its Q3 2026 earnings call. Key points include selling hardware to biopharma partners, restructuring to reduce cash burn, and AI-driven demand for lab data. The company ended the quarter with $285M in cash and no debt. Novo Nordisk is a notable partner.

finance.yahoo.com
$DNAMed

Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript

Ginkgo Bioworks (DNA) reported Q3 2026 earnings, showing a 44% improvement in net loss from continuing operations to $41M and a 58% improvement in adjusted EBITDA to -$22M. Revenue was $28M, down 6% YoY. The company highlighted cost-cutting efforts, reduced cash burn, and investments in autonomous labs. They ended the quarter with $285M in cash and reaffirmed full-year cash burn guidance of $125M-$150M.

finance.yahoo.com
$DNAMed

A GT investigation examines the funding, government ties and questionable business practices of seven US entities subject to China’s countermeasures

China’s Ministry of Commerce announced countermeasures against seven US entities, including Applied DNA Sciences (now BNB Plus Corp), Stratum Reservoir, Altana Technologies, Responsible Business Alliance, Verite Group, Human Rights in China, and Compliance Testing LLC, citing US sanctions over alleged forced labor in Xinjiang. The article links their roles to cotton traceability testing, AI supply-chain mapping, compliance services, and related government contracts.

globaltimes.cn
$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

yahoo.com
$DNAMed

Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of…

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebu

SEC EDGAR 8-K